Montag, 26. Juli 2021
Navigation öffnen
Anzeige:
Imfinzi NSCLC
Imfinzi NSCLC
JOURNAL ONKOLOGIE – STUDIE

Feasibility of Online MR-guided Radiotherapy on a 1.5T MR-Linac

Rekrutierend

NCT-Nummer:
NCT04172753

Studienbeginn:
Mai 2018

Letztes Update:
21.11.2019

Wirkstoff:
-

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
-

Sponsor:
University Hospital Tuebingen, University Hospital Tuebingen

Collaborator:
-

Studienlocations
(1 von 1)

University Hospital Tübingen, Department of Radiation Oncology
72076 Tübingen
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Daniel Zips, MD, Prof
Phone: +49 (0) 7071 29-85990
E-Mail: ro-info@med.uni-tuebingen.de

Cihan Gani, MD
Phone: +49 (0)7071 29-82165
E-Mail: cihan.gani@med.uni-tuebingen.de
» Ansprechpartner anzeigen

Studien-Informationen

Detailed Description:

Novel hybrid devices combine magnetic resonance imaging (MRI) and a linear accelerator in a single device. The superior soft tissue contrast compared with cone-beam computed tomography based treatment and the possibility for daily plan adaptation promise a higher precision of treatment, better target volume coverage and normal tissue sparing. In a first step the present study will test the feasibility of imaging and treatment on the 1.5 T MR-Linac.
 

Ein-/Ausschlusskriterien

Inclusion Criteria:

- existing indication for radiation therapy

- minimum age 18 years, no upper age limit

- capacity for consent

- Informed consent

Exclusion Criteria:

- contraindication for MRI (claustrophobia, metallic implants not applicable for MRI

- pregnancy

Studien-Rationale

Primary outcome:

1. Feasibility of online MR guided Radiotherapy (Time Frame - During every single patients treatment (i.e. between one to seven weeks after the first application of radiotherapy)):
Treatment of a patient is considered feasible when 85% of treatments were completed as planned in this patient



Secondary outcome:

1. Time analysis (Time Frame - During every single patients treatment (i.e. between one to seven weeks after the first application of radiotherapy)):
Time required for online MR guided radiotherapy
 

Studien-Arme

  • Experimental: Rectal and anal cancer
    In this arm patients with rectal and anal cancer are recruited.
  • Experimental: Prostate cancer
    In this arm patients with prostate cancer are recruited.
  • Experimental: Head and neck cancer
    In this arm patients with head and neck cancers are recruited.
  • Experimental: Esophageal cancer
    In this arm patients with esophageal cancer are recruited.
  • Experimental: Breast Cancer
    In this arm patients with breast cancer are recruited.
  • Experimental: Central nervous system tutors
    In this arm patients with tumors of the central nervous system are recruited.
  • Experimental: Palliative treatments
    In this arm patients with palliative treatments are recruited.
  • Experimental: Other
    In this arm patients with other tumors are recruited.
  • Experimental: Imaging only
    In this arm patients receive only imaging on the MR-Linac

Geprüfte Regime

  • Radiotherapy on the MR-Linac:
    Radiotherapy is performed on the 1.5 T MR Linac
  • Imaging on the MR Linac:
    Only imaging performed on the MR Linac

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren
EHA 2021
  • SCD: Häufigere und längere VOC-bedingte Krankenhausaufenthalte nach Vorgeschichte von VOC-Hospitalisierungen – Ergebnisse einer Beobachtungsstudie
  • Real-World-Daten des ERNEST-Registers untermauern Überlebensvorteil unter Ruxolitinib bei primärer und sekundärer Myelofibrose
  • I-WISh-Studie: Ärzte sehen TPO-RAs als beste Option, um anhaltende Remissionen bei ITP-Patienten zu erzielen
  • Phase-III-Studie REACH2 bei steroidrefraktärer akuter GvHD: Hohes Ansprechen auf Ruxolitinib auch nach Crossover
  • SCD: Neues digitales Schmerztagebuch zur tagesaktuellen Erfassung von VOCs wird in Beobachtungsstudie geprüft
  • Französische Real-World-Studie: Eltrombopag meist frühzeitig nach ITP-Diagnose im Rahmen eines Off-label-Use eingesetzt
  • Fortgeschrittene systemische Mastozytose: Französische Real-World-Studie bestätigt klinische Studiendaten zur Wirksamkeit von Midostaurin
  • CML-Management weitgehend leitliniengerecht, aber verbesserungsfähig – Ergebnisse einer Querschnittsbefragung bei britischen Hämatologen
  • Britische Real-World-Studie: Kardiovaskuläres Risikomanagement bei MPN-Patienten in der Primärversorgung nicht optimal
  • Myelofibrose: Früher Einsatz von Ruxolitinib unabhängig vom Ausmaß der Knochenmarkfibrose